Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats

[1]  J. Holst,et al.  Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[2]  W. Jusko,et al.  Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats , 2011, Journal of Pharmacology and Experimental Therapeutics.

[3]  G. Pacini,et al.  Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

[4]  S. Dejager,et al.  GLP-1: what is known, new and controversial in 2010? , 2010, Diabetes & metabolism.

[5]  P. Sexton,et al.  Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening , 2010, Molecular Pharmacology.

[6]  J. Cassidy,et al.  Pharmacokinetics and Pharmacodynamics of Inhaled GLP‐1 (MKC253): Proof‐of‐Concept Studies in Healthy Normal Volunteers and in Patients With Type 2 Diabetes , 2010, Clinical pharmacology and therapeutics.

[7]  Scott R. Drab.  Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects , 2010, Pharmacotherapy.

[8]  D. D’Alessio,et al.  Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes , 2010, Diabetes.

[9]  W. Cefalu.  The Physiologic Role of Incretin Hormones: Clinical Applications , 2010, The Journal of the American Osteopathic Association.

[10]  C. Beglinger,et al.  Pharmacokinetics and Pharmacodynamic Effects of Oral GLP‐1 and PYY3‐36: A Proof‐of‐concept Study in Healthy Subjects , 2008, Clinical pharmacology and therapeutics.

[11]  A. Young,et al.  Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. , 2008, International journal of pharmaceutics.

[12]  Andrea Mari,et al.  Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients , 2008, Diabetes.

[13]  S. Woods,et al.  Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[14]  D. Donnelly,et al.  Peptide binding at the GLP-1 receptor. , 2007, Biochemical Society transactions.

[15]  Jeppe Sturis,et al.  Small-molecule agonists for the glucagon-like peptide 1 receptor , 2007, Proceedings of the National Academy of Sciences.

[16]  J. Holst,et al.  Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus , 2007, Diabetologia.

[17]  W. Jusko,et al.  Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Administration in Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.

[18]  R. Bergman,et al.  Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. , 2006, American journal of physiology. Endocrinology and metabolism.

[19]  J. Gobburu,et al.  Population Pharmacokinetic–Pharmacodynamic Modeling of Subcutaneous and Pulmonary Insulin in Rats , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[20]  William J Jusko,et al.  Modeling the metabolic effects of terbutaline in β2‐adrenergic receptor diplotypes , 2004, Clinical pharmacology and therapeutics.

[21]  J. Holst,et al.  Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. , 2004, Diabetes.

[22]  G. Umpierrez,et al.  Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects , 2003, International Journal of Obesity.

[23]  A. Young,et al.  Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1 , 2001 .

[24]  A. Young,et al.  Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. , 2001, Metabolism: clinical and experimental.

[25]  Xia Li,et al.  Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[26]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[27]  A. Munafo,et al.  Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin. , 1999, The Journal of pharmacology and experimental therapeutics.

[28]  L. B. Knudsen,et al.  Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. , 1996, European journal of pharmacology.

[29]  J. Holst,et al.  Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM , 1996, Diabetologia.

[30]  J. Holst,et al.  Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. , 1996, The American journal of physiology.

[31]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[32]  R. Bergman,et al.  Glucose Tolerance and Insulin Action in Rats With Renovascular Hypertension , 1991, Hypertension.

[33]  J. Radziuk,et al.  Distribution and kinetics of glucose in rats analyzed by noncompartmental and compartmental analysis. , 1990, The American journal of physiology.

[34]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[35]  G. Adair.  THE HEMOGLOBIN SYSTEM VI. THE OXYGEN DISSOCIATION CURVE OF HEMOGLOBIN , 1925 .

[36]  N. Siddiqui.  Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. , 2009, Mymensingh medical journal : MMJ.

[37]  Siddiqui Ni.  Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. , 2009 .

[38]  J. Holst,et al.  Pharmacokinetics and Pharmacodynamics of Vildagliptin in Patients with Type 2 Diabetes Mellitus , 2007, Clinical pharmacokinetics.

[39]  J. Holst,et al.  Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.